Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 64 (Search time: 0.006 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2013PCR-mediated recombination can lead to artificial chimera formation, which may pose as BCR-ABL1 compound mutationsParker, W.; Phillis, S.; Yeung, D.; Hughes, T.; Scott, H.; Branford, S.; 55th American Society of Hematology Annual Meeting and Exhibition (07 Dec 2013 - 10 Dec 2013 : New Orleans, Louisiana)
2010Detection of low level nilotinib or dasatinib resistant BCR-ABL mutations by mass spectrometry in CML patients who fail Imatinib is highly predivtive of their subsequent clonal expansion when treated with the drug for which their mutation confers resistanceParker, W.; Ho, M.; Lawrence, R.; Irwin, D.; Scott, H.; Hughes, T.; Branford, S.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010Limiting the variability within a BCR-ABL quantitative PCR (RQ-PCR) assay is essential for optimal concordance of results between laboratories generating BCR-ABL values on an international reporting scaleFletcher, L.; Prime, J.; Phillis, S.; Jamison, B.; Field, C.; Prime, H.; Sullivan, B.; Yeoman, A.; Georgievski, J.; Parker, W.; Slader, C.; Hughes, T.; Branford, S.; Haematology Association of Australasia Annual Meeting (2010 : Auckland, New Zealand)
2010Contrasting response of patients with chronic myeloid leukaemia (CML) and the highly imatinib resistant L248V mutation that may be related to an increased propensity of some patients to form an associated deletion mutant with increased imatinib sensitivityPrime, H.; Romeo, G.; Phillis, S.; Field, C.; Jamison, B.; Prime, J.; Parker, W.; Joske, D.; Hughes, T.; Branford, S.; Haematology Association of Australasia Annual Meeting (2010 : Auckland, New Zealand)
2010Towards DNA-based monitoring of therapy in chronic myeloid leukemiaMorley, A.; Bartley, P.; Ross, D.; Latham, S.; Budgen, B.; Branford, S.; Hughes, T.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2009Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplificationRoss, D.; Schafranek, L.; Hughes, T.; Nicola, M.; Branford, S.; Score, J.
2010A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be AppropriateBranford, S.; Goh, H.; Izzo, B.; Beppu, L.; Ortmann, C.; Duniec, K.; Jin, Y.; Woodman, R.; Pane, F.; Kim, D.; Radich, J.; Hughes, T.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2007Monitoring disease responseHughes, T.; Branford, S.
2014Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) studyBaccarani, M.; Druker, B.; Branford, S.; Kim, D.; Pane, F.; Mongay, L.; Mone, M.; Ortmann, C.; Kantarjian, H.; Radich, J.; Hughes, T.; Cortes, J.; Guilhot, F.
2017Long-term outcomes of imatinib treatment for chronic myeloid leukemiaHochhaus, A.; Larson, R.; Guilhot, F.; Radich, J.; Branford, S.; Hughes, T.; Baccarani, M.; Deininger, M.; Cervantes, F.; Fujihara, S.; Ortmann, C.; Menssen, H.; Kantarjian, H.; O'Brien, S.; Druker, B.